- Did you mean
- mrsa
Search results - 70 results
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.
respond poorly to primary mRNA COVID-19 vaccination. A third dose has been shown to boost protection against severe disease and death in this immunosenescent population, but limited data is available on the ...
Homologous versus heterologous prime-boost COVID-19 vaccination: impact on clinical severity of Omicron among hospitalized COVID-19 patients in Belgium
confirmed by whole genome sequencing and vaccinated with a homologous (mRNA for prime/mRNA for boost) or heterologous (viral vector for prime/mRNA for boost) prime-boost vaccination schedule were included in ...
Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium
investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector-mRNA) versus homologous (mRNA-mRNA) prime-boost vaccination against severe outcomes ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
I Desombere; Kevin K. Ariën; Maria Goossens Source: PLOS Global Public Health, Volume 2, Issue 12 (2022) Keywords: COVID-19; fractional dose; reduced dose; mRNA vaccination; non-inferiority; SARS-CoV-2 Abstract: ...
Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
HPV mRNA; Oropharyngeal carcinoma; HPV-AHEAD Abstract: Background The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal ...
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
Stéphanie Humblet-Baron Source: Front Immunol, Volume 13 (2022) Keywords: 2019-nCoV Vaccine mRNA-1273 Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Immunocompromised Host mRNA Vaccines ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial (poster)
Publication Type: Scientific poster, presentation or proceeding Authors: Pieter Pannus; Stéphanie Depickère; Delphine Kemlin; Sarah Houben; Christophe Y. Neven; Leo Hendrickx; Johan Michiels; Willems, Elisabeth; Stéphane De Craeye; Antoine Francotte; Féli ...
Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
infectiousness of breakthrough cases (VE i) for a complete schedule of Ad26. COV2.S, ChAdOx1, BNT162 b2, mRNA-1273 as well as infection-acquired and hybrid immunity. We used a multilevel Bayesian model and ...
Prevalence of anti-SARS-CoV-2 antibodies in the general population in Belgium: Results of the second data collection (28/09/21-23/02/22)
mRNA vaccine compared to adenoviral-vectored vaccine reduced the risk of being seronegative by 90%. Health Topics: Coronavirus Coronavirus Coronavirus Service: Information sanitaire ...
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
BNT162 b2, while mRNA-1273 was associated with a lower risk (HR0.68, 95% CI 0.67-0.69). A prior COVID-19-infection was protective against a breakthrough infection (HR0.23, 95% CI 0.23-0.24), as was an mRNA ...